Close Menu

NEW YORK – Sphingotec announced its in vitro diagnostic assay for dipeptidyl peptidase 3 has been CE-IVD marked.

The company has launched the test.

According to the German diagnostic company, the assay, called IB10 Sphingotec DPP3, is the first CE-IVD-marked point-of-care biomarker test that can quantify DPP3 blood plasma levels. DPP3 is a biomarker that can predict outcomes in patients with cardiogenic shock when they are admitted to hospital intensive care units.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.